Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Michels, Sebastian
FIND, NCT03827850 / 2018-000399-13: FGFR Inhibitor in FGFR Dysregulated Cancer	Terminated	2	22	Europe	ERDAFITINIB, JNJ -42756493, WHO NUMBER 10147	Lung Cancer Group Cologne	Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer, NSCLC Stage IV	09/22	10/22
PACE-LUNG, NCT05281406 / 2019-004757-88: Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment	Recruiting	2	50	Europe	Osimertinib, Tagrisso, Pemetrexed, Cisplatin, Carboplatin	Goethe University	NSCLC Stage IIIB, NSCLC Stage IV	11/23	11/26